Two Cases of Heterozygous Familial Hypercholesterolemia in Children Effectively Managed With Pitavastatin and Ezetimibe Combination Therapy
Heterozygous familial hypercholesterolemia (HeFH) strongly predisposes individuals to atherosclerosis, including coronary artery disease, leading to death from cardiovascular diseases in > 60% of untreated cases. Appropriate intervention from childhood is necessary. In Japan, only pitavastatin is approved for pediatric FH. A poor response to statins makes treatment challenging; optimal intervention may require combination therapy.
Authors
- Kanako Irie
- Keiji Matsunaga (ORCID: https://orcid.org/0000-0003-3611-1143)
- Takashi Kusaka (ORCID: https://orcid.org/0000-0003-0790-737X)
- Tomoko Inoue (ORCID: https://orcid.org/0000-0001-5504-9352)
- Katsufumi Nishioka
- Sonoko Kondo (ORCID: https://orcid.org/0009-0005-9671-4300)
- Ryosuke Tani (ORCID: https://orcid.org/0000-0003-4831-567X)
- Takashi Iwase
- Takeo Kondo
- Tetsuo Minamino (ORCID: https://orcid.org/0000-0002-5424-4081)
Institutions
- Kagawa University (JP)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1002/ccr3.71018
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00